Treatment-related toxicities (occurring in >2 subjects)
| Toxicity . | Any grade . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . |
|---|---|---|---|---|---|
| PSN | 27 (79) | 16 (47) | 3 (9) | 8 (24) | 0 |
| Neutropenia | 26 (76) | 4 (12) | 1 (3) | 3 (9) | 18 (53) |
| Fatigue | 25 (74) | 17 (50) | 5 (15) | 3 (9) | 0 |
| Nausea | 24 (71) | 19 (56) | 4 (12) | 1 (3) | 0 |
| Anemia | 21 (62) | 12 (35) | 7 (21) | 2 (6) | 0 |
| Constipation | 19 (56) | 15 (44) | 4 (12) | 0 | 0 |
| Abdominal pain | 12 (35) | 5 (15) | 5 (15) | 2 (6) | 0 |
| Diarrhea | 12 (35) | 7 (21) | 4 (12) | 1 (3) | 0 |
| Febrile neutropenia | 12 (35) | 0 | 0 | 10 (29) | 2 (6)* |
| Alanine aminotransferase increased | 11 (32) | 8 (24) | 3 (9) | 0 | 0 |
| Vomiting | 11 (32) | 8 (24) | 2 (6) | 1 (3) | 0 |
| Alopecia | 9 (26) | 1 (3) | 8 (24) | 0 | 0 |
| Aspartate aminotransferase increased | 8 (24) | 8 (24) | 0 | 0 | 0 |
| Skin and subcutaneous disorders | 8 (24) | 5 (15) | 3 (9) | 0 | 0 |
| Oral mucositis | 7 (21) | 2 (6) | 4 (12) | 1 (3) | 0 |
| Arthralgia | 6 (18) | 5 (15) | 1 (3) | 0 | 0 |
| Bone pain | 6 (18) | 4 (12) | 2 (6) | 0 | 0 |
| Peripheral motor neuropathy | 6 (18) | 3 (9) | 3 (9) | 0 | 0 |
| Weight loss | 6 (18) | 1 (3) | 3 (9) | 2 (6) | 0 |
| Anorexia | 5 (15) | 3 (9) | 2 (6) | 0 | 0 |
| Headache | 5 (15) | 5 (15) | 0 | 0 | 0 |
| Thrombocytopenia | 5 (15) | 3 (9) | 2 (6) | 0 | 0 |
| Dehydration | 4 (12) | 3 (9) | 0 | 1 (3) | 0 |
| Fever | 4 (12) | 4 (12) | 0 | 0 | 0 |
| Gastroesophageal reflux | 4 (12) | 3 (9) | 1 (3) | 0 | 0 |
| Weakness | 4 (12) | 3 (9) | 1 (3) | 0 | 0 |
| Myalgia | 4 (12) | 4 (12) | 0 | 0 | 0 |
| Pain | 4 (12) | 1 (3) | 3 (9) | 0 | 0 |
| Cough | 3 (9) | 2 (6) | 1 (3) | 0 | 0 |
| Dizziness | 3 (9) | 3 (9) | 0 | 0 | 0 |
| Hypokalemia | 3 (9) | 3 (9) | 0 | 0 | 0 |
| Infusion-related reactions | 3 (9) | 1 (3) | 2 (6) | 0 | 0 |
| Upper respiratory tract infections | 3 (9) | 0 | 3 (9) | 0 | 0 |
| Toxicity . | Any grade . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . |
|---|---|---|---|---|---|
| PSN | 27 (79) | 16 (47) | 3 (9) | 8 (24) | 0 |
| Neutropenia | 26 (76) | 4 (12) | 1 (3) | 3 (9) | 18 (53) |
| Fatigue | 25 (74) | 17 (50) | 5 (15) | 3 (9) | 0 |
| Nausea | 24 (71) | 19 (56) | 4 (12) | 1 (3) | 0 |
| Anemia | 21 (62) | 12 (35) | 7 (21) | 2 (6) | 0 |
| Constipation | 19 (56) | 15 (44) | 4 (12) | 0 | 0 |
| Abdominal pain | 12 (35) | 5 (15) | 5 (15) | 2 (6) | 0 |
| Diarrhea | 12 (35) | 7 (21) | 4 (12) | 1 (3) | 0 |
| Febrile neutropenia | 12 (35) | 0 | 0 | 10 (29) | 2 (6)* |
| Alanine aminotransferase increased | 11 (32) | 8 (24) | 3 (9) | 0 | 0 |
| Vomiting | 11 (32) | 8 (24) | 2 (6) | 1 (3) | 0 |
| Alopecia | 9 (26) | 1 (3) | 8 (24) | 0 | 0 |
| Aspartate aminotransferase increased | 8 (24) | 8 (24) | 0 | 0 | 0 |
| Skin and subcutaneous disorders | 8 (24) | 5 (15) | 3 (9) | 0 | 0 |
| Oral mucositis | 7 (21) | 2 (6) | 4 (12) | 1 (3) | 0 |
| Arthralgia | 6 (18) | 5 (15) | 1 (3) | 0 | 0 |
| Bone pain | 6 (18) | 4 (12) | 2 (6) | 0 | 0 |
| Peripheral motor neuropathy | 6 (18) | 3 (9) | 3 (9) | 0 | 0 |
| Weight loss | 6 (18) | 1 (3) | 3 (9) | 2 (6) | 0 |
| Anorexia | 5 (15) | 3 (9) | 2 (6) | 0 | 0 |
| Headache | 5 (15) | 5 (15) | 0 | 0 | 0 |
| Thrombocytopenia | 5 (15) | 3 (9) | 2 (6) | 0 | 0 |
| Dehydration | 4 (12) | 3 (9) | 0 | 1 (3) | 0 |
| Fever | 4 (12) | 4 (12) | 0 | 0 | 0 |
| Gastroesophageal reflux | 4 (12) | 3 (9) | 1 (3) | 0 | 0 |
| Weakness | 4 (12) | 3 (9) | 1 (3) | 0 | 0 |
| Myalgia | 4 (12) | 4 (12) | 0 | 0 | 0 |
| Pain | 4 (12) | 1 (3) | 3 (9) | 0 | 0 |
| Cough | 3 (9) | 2 (6) | 1 (3) | 0 | 0 |
| Dizziness | 3 (9) | 3 (9) | 0 | 0 | 0 |
| Hypokalemia | 3 (9) | 3 (9) | 0 | 0 | 0 |
| Infusion-related reactions | 3 (9) | 1 (3) | 2 (6) | 0 | 0 |
| Upper respiratory tract infections | 3 (9) | 0 | 3 (9) | 0 | 0 |
Data are presented as n (%).
A 71-year-old patient with grade 4 neutropenic fever developed grade 5 sepsis.